We leverage our proprietary technology platform to design and deliver safe and effective therapies for neurological disorders.
According to the World Health Organisation (WHO), neurological disorders are one of the greatest threats to public health globally. Over the last couple of decades several strategies have failed to offer safe and effective therapeutic avenues to patients. At SMDG, we leverage our novel platform technology and library of new class of Peptide Conjugate nanoparticles (nanosystems) combined with the next generation nucleic acid therapies designed within our discovery programmes to deliver life saving therapies.
Our primary focus and an expanding portfolio of R & D programmes
Alzheimer's disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease—those with the late-onset type—symptoms first appear in their mid-60s.
Parkinson's disease (PD) is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty walking and talking.
Huntington's disease (HD) is a condition that stops parts of the brain working properly over time. It's passed on (inherited) from a person's parents. Huntington's disease is caused by a faulty gene that results in parts of the brain becoming gradually damaged over time. The patient gets gradually worse over time and is usually fatal after a period of up to 20 years. The symptoms usually start at 30 to 50 years of age, but can begin much earlier or later. Symptoms of Huntington's disease can include: difficulty concentrating and memory lapses, stumbling and clumsiness, involuntary jerking or fidgety, movements of the limbs and body, mood swings and personality changes, problems swallowing, speaking and breathing and difficulty moving.